{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T08:00:14Z","timestamp":1785052814192,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00210-026-05399-2","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:12:29Z","timestamp":1778217149000},"page":"16579-16582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ibrutinib-induced Sweet syndrome"],"prefix":"10.1007","volume":"399","author":[{"given":"Noor","family":"Almaani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain","family":"Al Ta\u2019ani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maram","family":"Abdaljaleel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris","family":"AlShammas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Alshorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"issue":"6","key":"5399_CR1","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.clindermatol.2020.06.012","volume":"38","author":"AJ Coromilas","year":"2020","unstructured":"Coromilas AJ, Gallitano SM (2020) Neutrophilic drug reactions. Clin Dermatol 38(6):648\u2013659. https:\/\/doi.org\/10.1016\/j.clindermatol.2020.06.012","journal-title":"Clin Dermatol"},{"issue":"3","key":"5399_CR2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/dad.0000000000000862","volume":"40","author":"L El Halabi","year":"2018","unstructured":"El Halabi L, Cherif-Rebai K, Michot J-M, Ghez D (2018) Ibrutinib-induced neutrophilic dermatosis. Am J Dermatopathol 40(3):198\u2013200. https:\/\/doi.org\/10.1097\/dad.0000000000000862","journal-title":"Am J Dermatopathol"},{"issue":"2","key":"5399_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1177\/1078155219856422","volume":"26","author":"R Ghasoub","year":"2020","unstructured":"Ghasoub R, Albattah A, Elazzazy S et al (2020) Ibrutinib-associated sever skin toxicity: a case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia \u2013 case report and literature review. J Oncol Pharm Pract 26(2):487\u2013491. https:\/\/doi.org\/10.1177\/1078155219856422","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"5399_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/ijd.17968","volume":"65","author":"C Girard","year":"2026","unstructured":"Girard C, Dereure O, Renuy J, Fizazi A (2026) Atypical neutrophilic dermatosis induced by ibrutinib: a dose-dependent cutaneous adverse reaction. Int J Dermatol 65(1):160\u2013162. https:\/\/doi.org\/10.1111\/ijd.17968","journal-title":"Int J Dermatol"},{"issue":"1","key":"5399_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/bjh.14302","volume":"180","author":"DJ Iberri","year":"2018","unstructured":"Iberri DJ, Kwong BY, Stevens LA, Coutre SE, Kim J, Sabile JM, Advani RH (2018) Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. Br J Haematol 180(1):164\u2013166. https:\/\/doi.org\/10.1111\/bjh.14302","journal-title":"Br J Haematol"},{"key":"5399_CR6","unstructured":"Ibrutinib | FDA approved drug that treats blood cancer | LLS (n.d.). https:\/\/www.lls.org\/drug\/ibrutinib. Accessed\u00a026 Dec 2024"},{"issue":"4","key":"5399_CR7","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jaad.2020.07.052","volume":"84","author":"A Mufti","year":"2021","unstructured":"Mufti A, Lytvyn Y, Maliyar K, Sachdeva M, Yeung J (2021) Drugs associated with development of pityriasis rubra pilaris: a systematic review. J Am Acad Dermatol 84(4):1071\u20131081. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.052","journal-title":"J Am Acad Dermatol"},{"key":"5399_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103696","volume":"174","author":"S Nocco","year":"2022","unstructured":"Nocco S, Andriano TM, Bose A, Chilov M, Godwin K, Dranitsaris G, Wu S, Lacouture ME, Roeker LE, Mato AR, Markova A (2022) Ibrutinib-associated dermatologic toxicities: a systematic review and meta-analysis. Crit Rev Oncol Hematol 174:103696. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103696","journal-title":"Crit Rev Oncol Hematol"},{"key":"5399_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14190","author":"A Pileri","year":"2020","unstructured":"Pileri A, Guglielmo A, Agostinelli C, Evangelista V, Bertuzzi C, Alessandrini A, Bruni F, Starace M, Massi A, Broccoli A, Patrizi A, Zinzani PL, Piraccini BM (2020) Cutaneous adverse\u2010events in patients treated with Ibrutinib. Dermatol Ther. https:\/\/doi.org\/10.1111\/dth.14190","journal-title":"Dermatol Ther"},{"issue":"3","key":"5399_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18030371","volume":"18","author":"E Robak","year":"2026","unstructured":"Robak E, Robak T (2026) Cutaneous adverse effects in patients treated with BTK inhibitors. Cancers Basel 18(3):371. https:\/\/doi.org\/10.3390\/cancers18030371","journal-title":"Cancers Basel"},{"key":"5399_CR11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","volume":"21","author":"V Sibaud","year":"2020","unstructured":"Sibaud V, Beylot-Barry M, Protin C et al (2020) Dermatological toxicities of Bruton\u2019s tyrosine kinase inhibitors. Am J Clin Dermatol 21:799\u2013812. https:\/\/doi.org\/10.1007\/s40257-020-00535-x","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"5399_CR12","doi-asserted-by":"publisher","first-page":"710","DOI":"10.20452\/pamw.3578","volume":"126","author":"M S\u0142awi\u0144ska","year":"2016","unstructured":"S\u0142awi\u0144ska M, Bara\u0144ska-Rybak W, Sobjanek M, Wilkowska A, Mital A, Nowicki R (2016) Ibrutinib-induced pyoderma gangrenosum. Pol Arch Med Wewn 126(9):710\u2013711. https:\/\/doi.org\/10.20452\/pamw.3578","journal-title":"Pol Arch Med Wewn"},{"key":"5399_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/dad.0000000000000980","author":"J Stewart","year":"2018","unstructured":"Stewart J, Bayers S, Vandergriff T (2018) Self-limiting Ibrutinib-induced neutrophilic panniculitis. Am J Dermatopathol. https:\/\/doi.org\/10.1097\/dad.0000000000000980","journal-title":"Am J Dermatopathol"},{"issue":"2","key":"5399_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s13671-022-00355-8","volume":"11","author":"EH Weiss","year":"2022","unstructured":"Weiss EH, Ko CJ, Leung TH, Micheletti RG, Mostaghimi A, Ramachandran SM, Rosenbach M, Nelson CA (2022) Neutrophilic dermatoses: a clinical update. Curr Dermatol Rep 11(2):89\u2013102. https:\/\/doi.org\/10.1007\/s13671-022-00355-8","journal-title":"Curr Dermatol Rep"},{"issue":"1","key":"5399_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/bjd.15193","volume":"177","author":"BC Wu","year":"2017","unstructured":"Wu BC, Patel ED, Ortega-Loayza AG (2017) Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. Br J Dermatol 177(1):72\u201383. https:\/\/doi.org\/10.1111\/bjd.15193","journal-title":"Br J Dermatol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05399-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05399-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05399-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T07:02:05Z","timestamp":1785049325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05399-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["5399"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05399-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors assert that all procedures contributing to this work comply with the Helsinki Declaration.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient consent obtained for publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}